

**PRIOR AUTHORIZATION REQUEST FORM  
HYALURONIC ACID**

Euflexxa®, Gel-One®, Gelsyn-3®, Genvisc®, Hyalgan®, Orthovisc®, Supartz®, Synvisc®, Synvisc-One®, Vicso-3™

**For authorization, please answer each question and fax this form PLUS chart notes back to the Advantage U Prior Authorization Department at 801-213-1547.**

If you have prior authorization questions, please call Advantage U for assistance: 888-605-0858

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Product being requested:**  Euflexxa® (1% sodium-hyaluronate),  Gel-One® (cross-linked hyaluronate),  Gelsyn-3® (hyaluronic acid),  Genvisc® (sodium hyaluronate),  Hyalgan® (sodium hyaluronate),  Orthovisc® (sodium hyaluronate),  Supartz® (sodium hyaluronate),  Synvisc® (hylan G-F 20) ,  Synvisc-One® (hylan G-F 20),  Visco-3™ (sodium hyaluronate)

Dosing/Frequency: \_\_\_\_\_

**If the request is for reauthorization, proceed to reauthorization section**

Questions	Yes	No	Comments/Notes
1. Is the request for treatment of Osteoarthritis of the knee?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have a body mass index (BMI) ≤ 40 kg/m2?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Is the request made by, or in consultation with, a sports medicine physician, physical medicine and rehabilitation physician, rheumatologist, orthopedist, or a pain management specialist?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Does the member have a diagnosis of grade II or III primary osteoarthritis of the knee confirmed with imaging?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. Is the member experiencing moderate to severe functional impairment evidence by at least 1 of the following: <ul style="list-style-type: none"> <li>• Functional impairment with poor mobility</li> <li>• Increased pain with prolonged standing</li> <li>• Frequent flares requiring use of analgesics, NSAIDs, or corticosteroids?</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
6. Has the member had a trial and failure of physician directed exercise or physical therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
7. Has the member had a trial and failure of acetaminophen and/or topical capsaicin, and prescription strength non-steroidal anti-inflammatory drugs (NSAIDs) for ≥3 months?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

8. Has the member had a trial and failure of an intra-articular steroid injection (triamcinolone) within the past 6 months?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
9. Has the member tried an orthotic device such as a knee brace?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
10. Does the physician anticipate a total knee replacement within the next 6 months?	<input type="checkbox"/>	<input type="checkbox"/>	
<b>REAUTHORIZATION</b>			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does documentation show decreased pain and improved functional capacity since first treatment cycle?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician's Signature:			

Policy PHARM-MA-M001  
 Origination Date: 01/01/2022  
 Reviewed/Revised Date: 11/21/2022  
 Next Review Date: 11/21/2022  
 Current Effective Date: 12/01/2022

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.